Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeMedia CenterPress releases Medical technologiesBiosense Webster Announces Launch of the CARTO® 3 MEM Base Version

      Biosense Webster Announces Launch of the CARTO® 3 MEM Base Version

      Share Article
      share to

      Diamond Bar, CA - August 13, 2012 Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the new CARTO® 3 MEM (Multi-Electrode Mapping)Version in the United States.

      NEW Multi-Electrode Mapping Technology
      The CARTO® 3 MEM Version is the latest advancement on the CARTO® 3 System platform. Based on market–leading electromagnetic technology, the new CARTO® 3 MEM Version provides a fast method for mapping and diagnosing arrhythmias, while using sensor-based MEM-enabled catheters to maintain a high degree of anatomical accuracy. The new PENTARAY® Nav Catheter is equipped with the electromagnetic sensor, allowing for accurate visualization of electrode position on the CARTO® 3 System and higher resolution signals.

      “Multi-electrode mapping represents a significant advancement in mapping technology, allowing physicians to acquire multiple mapping points simultaneously with a high level of detail and CARTO® 3 System accuracy,” said Dr. Vivek Reddy, Mount Sinai School of Medicine. “Combined with the new PENTARAY® Nav Catheter, you can reduce the number of required catheter maneuvers to quickly diagnose any arrhythmia. This further supports the safety, effectiveness and efficiency of cardiac ablation procedures for patients.”

      About AF and cardiac ablation
      Atrial Fibrillation (AF) is the most prevalent arrhythmia, and is a leading cause of stroke among people 65 years and older. Worldwide, it is estimated that 20 million people have AF, yet only ~130,000 are treated with ablation every year. The public health implications of AF are a growing concern because those with AF are at an increased risk of morbidity and mortality as well as a reduced quality of life. Today, most patients with AF are treated with anti-arrhythmic drugs (AADs), even though about half of them are refractory to these drugs.

      Cardiac Ablation offers a safe and efficacious alternative to treat cardiac arrhythmias. During cardiac ablation, energy is delivered through the catheter to those areas of the heart muscle causing the abnormal heart rhythm. This energy “disconnects” the pathway of the abnormal rhythm. Cardiac ablation is commonly used for “simple” arrhythmias, like Wolff-Parkinson-White Syndrome and atrioventricular nodal re-entry tachycardia (AVNRT), and is increasingly being used for more complex arrhythmias like ventricular tachycardia and atrial fibrillation. THERMOCOOL®Navigation Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO® Systems (excluding the NAVISTAR® RMT THERMOCOOL® Catheter).

      Dr. Reddy is compensated for his services as a member of the company’s scientific advisory board and provides other consulting services.

      About Biosense Webster, Inc.
      Biosense Webster, Inc., a Johnson & Johnson company, pioneered EP diagnostic catheters more than 20 years ago and continues to lead the industry as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. As the leader in EP navigation systems and ablation therapy, Biosense Webster, Inc. has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions. For more information about Biosense Webster and its products, please visit: (this site is intended for US visitors only).

      Biosense Webster, Inc.
      Sandy Pound, 908-218-2720
      (o) 908-218-2720
      (m) 908-432-2829

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.